Phase III clinical trial - Sein métastatique HER2+

ALPHABET
Sein métastatique HER2+
Ouvert depuis le: 04.20.2024
Site: Saint-Cloud
Public cible
Adulte
Randomized phase III trial of the administration of trastuzumab + Alpelisib +/- fulvestrant versus trastuzumab + chemotherapy in patients with a PIK3CA mutation and previously treated for advanced HER2+ cancer
Description de l'essai
To determine whether alpelisib (PI3K inhibitor) + trastuzumab improves efficacy, measured by PFS (Progression Free Survival), compared to the combination of trastuzumab + chemotherapy (vinorelbine, capecitabine or eribulin) of the physician's choice, in patients with HER2+/RH-PIK3CA mutated advanced breast cancer.;À Determine whether alpelisib (PI3K inhibitor) + trastuzumab improves efficacy, measured by PFS (Progression Free Survival), compared to the combination of trastuzumab + chemotherapy (vinorelbine, capecitabine or eribulin) of the physician's choice, in patients with HER2+/RH+ PIK3CA mutated advanced breast cancer.
Vignette
FRANCOIS-CLEMENT BIDARD
Investigateur principal
Vignette
FRANCOIS-CLEMENT BIDARD
Investigateur principal